News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
778,203 Results
Type
Article (53845)
Company Profile (319)
Press Release (724029)
Multimedia
Podcasts (144)
Webinars (25)
Section
Business (218850)
Career Advice (2661)
Deals (37056)
Drug Delivery (129)
Drug Development (85410)
Employer Resources (184)
FDA (17464)
Job Trends (15997)
News (369242)
Policy (35593)
Tag
Academia (2875)
Academic (1)
Accelerated approval (28)
Adcomms (30)
Allergies (138)
Alliances (54179)
ALS (174)
Alzheimer's disease (1725)
Antibody-drug conjugate (ADC) (290)
Approvals (17661)
Artificial intelligence (537)
Autoimmune disease (137)
Automation (34)
Bankruptcy (368)
Best Places to Work (12212)
BIOSECURE Act (22)
Biosimilars (189)
Biotechnology (208)
Bladder cancer (151)
Brain cancer (56)
Breast cancer (623)
Cancer (4714)
Cardiovascular disease (397)
Career advice (2252)
Career pathing (39)
CAR-T (284)
CDC (50)
Celiac Disease (1)
Cell therapy (753)
Cervical cancer (36)
Clinical research (72184)
Collaboration (1647)
Company closure (5)
Compensation (1084)
Complete response letters (57)
COVID-19 (2892)
CRISPR (90)
C-suite (779)
Cystic fibrosis (146)
Data (6017)
Decentralized trials (2)
Denatured (53)
Depression (126)
Diabetes (493)
Diagnostics (6982)
Digital health (41)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (259)
Drug pricing (191)
Drug shortages (31)
Duchenne muscular dystrophy (221)
Earnings (94280)
Editorial (59)
Employer branding (23)
Employer resources (163)
Events (125777)
Executive appointments (991)
FDA (20421)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (23)
Funding (1463)
Gene editing (200)
Generative AI (52)
Gene therapy (610)
GLP-1 (1015)
Government (5082)
Grass and pollen (8)
Guidances (379)
Healthcare (20181)
HIV (54)
Huntington's disease (44)
IgA nephropathy (84)
Immunology and inflammation (260)
Immuno-oncology (44)
Indications (80)
Infectious disease (3154)
Inflammatory bowel disease (192)
Inflation Reduction Act (16)
Influenza (109)
Intellectual property (226)
Interviews (459)
IPO (17055)
IRA (54)
Job creations (4150)
Job search strategy (1878)
Kidney cancer (16)
Labor market (82)
Layoffs (588)
Leadership (36)
Legal (8803)
Liver cancer (94)
Longevity (13)
Lung cancer (641)
Lymphoma (366)
Machine learning (40)
Management (63)
Manufacturing (751)
MASH (166)
Medical device (14542)
Medtech (14586)
Mergers & acquisitions (21018)
Metabolic disorders (1256)
Multiple sclerosis (154)
NASH (19)
Neurodegenerative disease (316)
Neuropsychiatric disorders (82)
Neuroscience (2927)
NextGen: Class of 2026 (7114)
Non-profit (4949)
Now hiring (61)
Obesity (590)
Opinion (299)
Ovarian cancer (157)
Pain (187)
Pancreatic cancer (214)
Parkinson's disease (278)
Partnered (35)
Patents (474)
Patient recruitment (438)
Peanut (59)
People (62630)
Pharmaceutical (73)
Pharmacy benefit managers (30)
Phase I (22485)
Phase II (31600)
Phase III (23724)
Pipeline (4353)
Policy (300)
Postmarket research (2862)
Preclinical (9806)
Press Release (69)
Prostate cancer (233)
Psychedelics (50)
Radiopharmaceuticals (282)
Rare diseases (795)
Real estate (6468)
Recruiting (74)
Regulatory (25950)
Reports (52)
Research institute (2613)
Resumes & cover letters (429)
Rett syndrome (26)
RNA editing (15)
RSV (78)
Schizophrenia (148)
Series A (244)
Series B (183)
Service/supplier (13)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (159)
Sponsored (44)
Startups (3903)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (86)
The Weekly (89)
Vaccines (1048)
Venture capital (85)
Weight loss (394)
Women's health (78)
Worklife (20)
Date
Today (240)
Last 7 days (741)
Last 30 days (2028)
Last 365 days (31774)
2026 (758)
2025 (31594)
2024 (36625)
2023 (41559)
2022 (52856)
2021 (57645)
2020 (56412)
2019 (49680)
2018 (37587)
2017 (34565)
2016 (34613)
2015 (40686)
2014 (34808)
2013 (30359)
2012 (32264)
2011 (32652)
2010 (31046)
Location
Africa (948)
Alabama (82)
Alaska (7)
Arizona (306)
Arkansas (13)
Asia (43821)
Australia (7258)
California (10873)
Canada (3196)
China (1068)
Colorado (461)
Connecticut (480)
Delaware (324)
Europe (97983)
Florida (1603)
Georgia (348)
Hawaii (2)
Idaho (66)
Illinois (855)
India (59)
Indiana (509)
Iowa (22)
Japan (403)
Kansas (128)
Kentucky (39)
Louisiana (25)
Maine (81)
Maryland (1378)
Massachusetts (8010)
Michigan (319)
Minnesota (618)
Mississippi (6)
Missouri (134)
Montana (34)
Nebraska (28)
Nevada (118)
New Hampshire (81)
New Jersey (2935)
New Mexico (31)
New York (2904)
North Carolina (1475)
North Dakota (10)
Northern California (5221)
Ohio (326)
Oklahoma (21)
Oregon (44)
Pennsylvania (2208)
Puerto Rico (20)
Rhode Island (47)
South America (1321)
South Carolina (60)
South Dakota (1)
Southern California (4216)
Tennessee (170)
Texas (1693)
United States (39193)
Utah (322)
Vermont (1)
Virginia (260)
Washington D.C. (80)
Washington State (901)
West Virginia (4)
Wisconsin (101)
Wyoming (2)
778,203 Results for "social and scientific systems inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuropsychiatric disorders
Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial
The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress disorder.
October 21, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder
January 6, 2026
·
6 min read
Press Releases
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
December 18, 2025
·
7 min read
Press Releases
Rosalind Franklin University Secures $1.7M in NIH Funding to Advance Research on Social Recognition Mechanisms in Schizophrenia and Autism Spectrum Disorders
December 19, 2025
·
1 min read
Press Releases
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
November 3, 2025
·
7 min read
Press Releases
CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones
December 30, 2025
·
5 min read
Press Releases
Hemostemix’s Social Media for Investors and Florida’s No-Option Patients
August 20, 2025
·
9 min read
Press Releases
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership
December 10, 2025
·
6 min read
Genetown
Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report
Thermo Fisher Scientific Inc., the world leader in serving science, released its 2023 Corporate Social Responsibility report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.
May 28, 2024
·
3 min read
Press Releases
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
October 20, 2025
·
6 min read
1 of 77,821
Next
